Journal of managed care & specialty pharmacy
短名 | JMCP |
Journal Impact | 2.26 |
国际分区 | PHARMACOLOGY & PHARMACY(Q3) |
期刊索引 | SCI Q3中科院 4 区 |
ISSN | 2376-0540, 2376-1032 |
h-index | 75 |
国内分区 | 医学(4区)医学卫生保健与服务(4区)医学药学(4区) |
JMCP 欢迎在美国境外进行的与我们的读者相关的研究。我们的听众主要关注基于大量人群的证据设计处方集覆盖范围、健康福利设计和药物计划的政策。在美国以外进行的药剂师干预研究已经在美国进行了广泛研究,以及在美国以外的非管理式医疗环境(例如医院或社区药房)中进行的小样本研究通常对我们的读者群。然而,JMCP 的读者对在大量人群中评估的健康结果和成本的研究为处方集覆盖范围、健康福利设计和药物计划提供证据非常感兴趣。
期刊主页投稿网址涉及主题 | 医学生物政治学法学内科学经济病理护理部家庭医学经济增长医疗保健心理学化学外科数学精神科生物化学药理学药店统计业务计算机科学梅德林社会学遗传学环境卫生药方人口学急诊医学回顾性队列研究 |
出版信息 | 出版商: Academy of Managed Care Pharmacy (AMCP),出版周期: ,期刊类型: journal |
基本数据 | 创刊年份: 2014,原创研究文献占比: 96.55%,自引率:8.70%, Gold OA占比: 0.71% |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Multidisciplinary perspectives in <i>Demodex</i> blepharitis: A new view of treatment from clinical, payer, and patient perspectives
2024-10-1
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer
2024-9-11
Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan
2024-9-11
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States
2024-9-9
Nonalcoholic steatohepatitis/metabolic dysfunction–associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective
2024-9-1
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes
2024-9-1
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs
2024-9-1
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
2024-9-1
Budget impact models for lung cancer interventions: A systematic literature review
2024-9-1
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment
2024-9-1
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer
2024-9-1
US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance
2024-9-1
Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder
2024-9-1
Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis
2024-9-1
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder
2024-9-1
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: a microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid
2024-8-7
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease
2024-8-5
Understanding racial disparities in health care expenditures for cervical cancer
2024-8-1
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes
2024-8-1
Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018
2024-8-1
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study
2024-8-1
A primer on copay accumulators, copay maximizers, and alternative funding programs
2024-8-1
Evolving oncology care management trends in the United States: A survey among health care decision makers
2024-8-1
Benefits of dapagliflozin in chronic kidney disease for US commercial payers: A cost-offset analysis
2024-8-1
Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States
2024-8-1
Total cost of care of Medicare Advantage beneficiaries participating in an appointment-based model in a national pharmacy chain
2024-8-1
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program
2024-8-1
The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B
2024-8-1
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
2024-7-27
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting
2024-7-24
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments
2024-7-22
Stakeholder perspectives on the sustainability of the United States biosimilars market
2024-7-16
Racial and social inequities in medication use: A review of articles responding to the <i>Journal of Managed Care</i> + <i>Specialty Pharmacy</i>’s Call to Action
2024-7-1
Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them
2024-7-1
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer
2024-7-1
Affordability and adherence gains for Medicare Part D low-income subsidy recipients when low-income subsidy benefits expanded in 2024
2024-7-1
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program
2024-7-1
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States
2024-7-1
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study
2024-7-1
Editor’s Note
2024-7-1
Reducing disparities in medication use: Responding to managed care pharmacy’s imperatives
2024-7-1
Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy
2024-7-1
Clinical and economic evaluation of tralokinumab for atopic dermatitis
2024-7-1
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program
2024-7-1
Clinical characteristics and treatment patterns of patients with <i>NTRK</i> fusion–positive solid tumors: A multisite cohort study at US academic cancer centers
2024-7-1
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative
2024-7-1
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B
2024-6-26
Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives
2024-6-21
Impact of a tubeless, disposable insulin pump on emergency department visits and inpatient admissions among a Medicare population
2024-6-17
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction–associated steatohepatitis: A US cohort study
2024-6-7
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远